ArticleFrontiers in pharmacology2019
Immediate Effects of Dasatinib on the Migration and Redistribution of Naïve and Memory Lymphocytes Associated With Lymphocytosis in Chronic Myeloid Leukemia Patients.
Article in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 14 citations in OpenAlex.
- Dasatinib reversibly disrupts T cell motility and activation in lymph nodes.Science advances · 2026Article
- Inhibiting the Secreted RGDKGE Collagen Peptide Selectively Controls CD8The American journal of pathology · 2026Article
- Targeting Cellular Senescence to Enhance Human Endometrial Stromal Cell Decidualization and Inhibit Their Migration.Biomolecules · 2025Article
- Microfluidic single-cell migration chip reveals insights into the impact of extracellular matrices on cell movement.Lab on a chip · 2023Article
- Dasatinib-induced spleen contraction leads to transient lymphocytosis.Blood advances · 2023Article
- Antioxidant activity of novel nitrogen scaffold with docking investigation and correlation of DFT stimulation.RSC advances · 2023Article
- Microwave-assisted synthesis, antioxidant activity, docking simulation, and DFT analysis of different heterocyclic compounds.Scientific reports · 2023Article
- Primary Effusion Lymphoma in an HIV-Negative Patient with Chronic Myeloid Leukemia Treated with Dasatinib.Pathobiology : journal of immunopathology, molecular and cellular biology · 2023Article
- Impact of senolytic treatment on immunity, aging, and disease.Frontiers in aging · 2023Review
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 11 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.